84.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BPMC Giù?
Forum
Previsione
Precedente Chiudi:
$84.69
Aprire:
$84.01
Volume 24 ore:
934.03K
Relative Volume:
0.91
Capitalizzazione di mercato:
$5.32B
Reddito:
$434.41M
Utile/perdita netta:
$-128.05M
Rapporto P/E:
-39.90
EPS:
-2.11
Flusso di cassa netto:
$-250.52M
1 W Prestazione:
+2.00%
1M Prestazione:
-5.12%
6M Prestazione:
-1.67%
1 anno Prestazione:
-3.07%
Blueprint Medicines Corp Stock (BPMC) Company Profile
Nome
Blueprint Medicines Corp
Settore
Industria
Telefono
617-374-7580
Indirizzo
45 SIDNEY STREET, CAMBRIDGE, MA
Confronta BPMC con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BPMC
Blueprint Medicines Corp
|
84.18 | 5.32B | 434.41M | -128.05M | -250.52M | -2.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-20 | Ripresa | Morgan Stanley | Equal-Weight |
2025-03-18 | Iniziato | Wolfe Research | Outperform |
2025-03-17 | Iniziato | Jefferies | Buy |
2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
2024-11-14 | Iniziato | JP Morgan | Overweight |
2024-10-24 | Iniziato | UBS | Neutral |
2024-05-14 | Iniziato | Stephens | Overweight |
2024-05-06 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
2023-10-27 | Aggiornamento | Oppenheimer | Perform → Outperform |
2023-08-21 | Reiterato | Needham | Buy |
2023-07-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2023-06-05 | Downgrade | SVB Securities | Market Perform → Underperform |
2023-01-03 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
2022-12-14 | Iniziato | Needham | Buy |
2022-11-02 | Downgrade | Oppenheimer | Outperform → Perform |
2022-09-14 | Iniziato | Berenberg | Buy |
2022-07-08 | Iniziato | Oppenheimer | Outperform |
2022-06-27 | Iniziato | Wells Fargo | Underweight |
2022-06-10 | Downgrade | Citigroup | Neutral → Sell |
2022-06-01 | Aggiornamento | Jefferies | Hold → Buy |
2022-03-01 | Iniziato | Citigroup | Neutral |
2022-02-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2022-01-25 | Aggiornamento | Stifel | Hold → Buy |
2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
2021-09-30 | Ripresa | Stifel | Hold |
2021-06-04 | Ripresa | Robert W. Baird | Outperform |
2021-03-31 | Iniziato | Credit Suisse | Neutral |
2020-12-03 | Iniziato | Stifel | Hold |
2020-11-02 | Reiterato | H.C. Wainwright | Buy |
2020-11-02 | Downgrade | Jefferies | Buy → Hold |
2020-10-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-07-15 | Reiterato | H.C. Wainwright | Buy |
2020-05-05 | Iniziato | Barclays | Equal Weight |
2020-03-17 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
2019-11-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
2019-10-22 | Iniziato | JMP Securities | Mkt Outperform |
2019-10-03 | Iniziato | H.C. Wainwright | Buy |
2019-09-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2019-08-29 | Iniziato | Piper Jaffray | Neutral |
2019-08-15 | Ripresa | Raymond James | Mkt Perform |
2019-07-18 | Iniziato | Deutsche Bank | Buy |
2019-05-23 | Ripresa | Goldman | Buy |
2019-04-03 | Iniziato | Morgan Stanley | Overweight |
2018-09-25 | Iniziato | Leerink Partners | Outperform |
2017-12-11 | Reiterato | Goldman | Buy |
Mostra tutto
Blueprint Medicines Corp Borsa (BPMC) Ultime notizie
BPMC stock rated an Equal-weight by Morgan Stanley - knoxdaily.com
Wedbush Decreases Earnings Estimates for Blueprint Medicines - Defense World
What is Wedbush’s Forecast for BPMC Q3 Earnings? - Defense World
Wedbush Reaffirms “Outperform” Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Blueprint Medicines (BPMC) - The Globe and Mail
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Franklin Resources Inc. Lowers Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
O Shaughnessy Asset Management LLC Reduces Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines' (BPMC) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Blueprint Medicines Corp (BPMC) Shares Plummet Below 1-Year High - News Heater
Blueprint Medicines’ (BPMC) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Breaking Down Blueprint Medicines: 14 Analysts Share Their Views - Benzinga
Blueprint Medicines at Needham Conference: Strategic Growth in Mastocytosis - Investing.com
Blueprint Medicines Corp [BPMC] stock was sold by Haviland Kate at the price of US$0.22 million - knoxdaily.com
Blueprint Medicines stock hits 52-week low at $80.64 - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Vanguard Group Inc. - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Corebridge Financial Inc. - The AM Reporter
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference - PR Newswire
Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy? - Insider Monkey
Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock (NASDAQ:BPMC) - Seeking Alpha
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion - Investing.com
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion By Investing.com - Investing.com UK
Blueprint Medicines COO Christina Rossi sells shares worth $216,075 By Investing.com - Investing.com Canada
Blueprint Medicines COO Christina Rossi sells shares worth $216,075 - Investing.com India
Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts - Yahoo Finance
PNC Financial Services Group Inc. Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts - Benzinga
Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March - Insider Monkey
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target - Investing.com
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target By Investing.com - Investing.com UK
Blueprint Medicines’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Victory Capital Management Inc. - Defense World
Wolfe Research initiates Blueprint Medicines with Outperform rating - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Now Covered by Jefferies Financial Group - Defense World
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
241,966 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Raymond James Financial Inc. - Defense World
Blueprint Medicines initiated with a Buy at Jefferies - TipRanks
Jefferies sets Blueprint Medicines stock Buy rating, $135 target - Investing.com
Jefferies sets Blueprint Medicines stock Buy rating, $135 target By Investing.com - Investing.com Philippines
Blueprint Medicines (NASDAQ:BPMC) Shares Down 1.6% – Here’s Why - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock By Investing.com - Investing.com Australia
Steward Partners Investment Advisory LLC Lowers Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock - Investing.com India
Charles Schwab Investment Management Inc. Purchases 7,165 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook By Investing.com - Investing.com South Africa
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook - Investing.com
US Bancorp DE Sells 1,988 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Corp Azioni (BPMC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):